Frequently used abbreviations
• ITAM = immunoreceptor tyrosine-based activation motif 
Modeling method
To match the level of detail present in the data (population-averaged phosphorylation levels of individual amino acid residues), reactions must factor in specific protein sites, which increases the number of species that must be considered. For example, if one considers three sites of phosphorylation in the kinase LCK (Y192, Y394, and Y505, all of which are considered in our model), the molecule has 2 3 = 8 possible phosphorylation states. When the multiple binding and phosphorylation states of all proteins of interest are considered, the large number of possible species is an obstacle to formulation of a model via traditional means, such as coupled ordinary differential equations. An alternative means of model specification that captures chemical kinetics like a traditional model but is better suited for modeling with site-specific resolution is rulebased modeling. In this approach, a domain-specific language is used to define local rules for biomolecular interactions. The modeling language that we have used is the BioNetGen language
Crosslinking reagents
Jurkat T cells were stimulated with anti-CD3, anti-CD28, and secondary antibodies, which are commonly used reagents for experimental stimulation of T cells [91] because antibody-mediated crosslinking recapitulates intracellular signaling events that lead to cellular activation [23] .
a. α-CD28 α-CD28 antibody (CD28.2) was purchased from Santa Cruz Biotechnology, Inc. It is a mouse monoclonal antibody raised against human CD28-transfected murine T cell hybridoma. b. α-CD3 α-CD3 antibody (HIT3a) was purchased from Santa Cruz Biotechnology, Inc. It is a mouse monoclonal antibody. c. α-IgG α-IgG antibody (Z 0420) was purchased from DakoCytomation. It is a polyclonal goat antimouse antibody.
These antibodies trigger signaling through clustering of TCR and CD28 molecules, which mimics the outcome of interactions between a T cell and an antigen-presenting cell. These antibodies have the potential to induce large receptor/co-receptor oligomers, but as a simplification that captures the essential action of these stimuli, we model them as three virtual ligands that induce CD28 homodimers (Ligand 1), CD28/TCR heterodimers (Ligand 2), and TCR homodimers (Ligand 3).
Molecule type definitions:
a. Lig1(aCD28, aCD28) b. Lig2(aCD28, aCD3) c. Lig3(aCD3, aCD3) The components aCD3 and aCD28 are considered to be binding sites that interact with CD3 and CD28, respectively. 2. TCR/CD3 complex.
TCR/CD3 is a multimeric complex of αβ, γ, and δ heterodimers and a ζζ homodimer [92, 93, 94] . The CD3 , γ, and δ molecules each contain one immunoreceptor tyrosine-based activation motif (ITAM), and ζ contains three. These motifs comprise two tyrosines on either side of a consensus sequence [95] . Phosphorylation of a ζ ITAM allows the TCR to recruit the kinase ZAP70 [96] . The extracellular portion of CD3 is recognized by α-CD3 antibodies [97, 98, 99] . The ITAM of CD3 overlaps with a proline-rich sequence (PRS) that interacts with NCK [36] [100].
Molecule type definition:
TCR(epitope,Y149 D∼0∼P,Y171 G∼0∼P,Y111∼0∼P,Y123∼0∼P,fynbind,PRS E,Y188 E∼0∼P,Y199 E∼0∼P)
Y111 and Y123 are sites in the ζ chain. Sites and motifs in the δ, , and γ chains are designated with D, E, and G, respectively. The region of the TCR that interacts with FYN is designated fynbind.
CD28
In addition to ligation of the TCR, ligation of a co-receptor such as CD28 is needed for T-cell activation. CD28 is a homodimeric glycoprotein composed of two identical disulfide-linked chains [101] that can interact with ligands of the B7 family [102, 103, 104] . Molecule type definition:
The component epitope represents the extracellular region that is bound by the α-CD28 antibody. The components PRS1 and PRS2 represent the distinct PRS motifs that bind LCK and ITK, respectively. 4. LCK LCK is a Src-family kinase (SFK 
Interactions in Model
Receptor stimulation 1. CD28 cross-linking. Ligand-induced clustering of CD28 complexes was modeled as follows:
The first rule represents initial binding and the second rule represents cross-linking.
2. CD3 cross-linking. Ligand-induced clustering of TCR/CD3 complexes was modeled as follows:
a. Lig3(aCD3,aCD3) + TCR(epitope) <-> Lig3(aCD3!1,aCD3).TCR(epitope!1) kfl,krl b. Lig3(aCD3!1,aCD3).TCR(epitope!1) + TCR(epitope) <-> Lig3(aCD3!1,aCD3!2).TCR(epitope!1).TCR(epitope!2) kfl m,krl
The first rule represents initial binding and the second represents cross-linking.
3. CD3/CD28 cross-linking. Ligand-induced co-clustering of TCR and CD28 was modeled as follows:
a. Lig2(aCD28,aCD3) + CD28(epitope) <-> Lig2(aCD28!1,aCD3).CD28(epitope!1) kfl,krl b. Lig2(aCD28!1,aCD3).CD28(epitope!1) + TCR(epitope) <-> Lig2(aCD28!1,aCD3!2).CD28(epitope!1).TCR(epitope!2) kfl m,krl c. Lig2(aCD28,aCD3) + TCR(epitope) <-> Lig2(aCD28,aCD3!1).TCR(epitope!1) kfl,krl d. 
Recruitment of signaling proteins to receptors
4. LCK binds CD28. The SH3 domain of LCK binds the C-terminal PRS ( 208 PYAP) in CD28. CD28 signaling requires the presence of proline residues in CD28 as well as the SH3 domain of LCK [173] . Cross-linking of CD28 is followed by an increase in LCK kinase activity [118, 119, 174] . The interaction of LCK and CD28 is modeled using the following rule: The first rule represents interactions between NCK and a TCR that is unphosphorylated at Y188 of CD3E. The second rule represents dissociation of NCK induced by phosphorylation of Y188 [36] . We assume that phosphorylation of Y188 takes place even when NCK is bound (i.e., phosphorylation is not inhibited) because the phosphorylation dynamics of this site is comparable to that of other ITAMs in our data (see Supplementary Fig. S6 ).
8. ZAP70 binds phosphorylated Y111 in the ζ chain of TCR. ZAP70 has two SH2 domains that bind phosphorylated ITAM residues in the TCR [130] . In the model, the two SH2 domains are treated as a single site. Binding of ZAP70 to phosphorylated pY111 is modeled as follows:
TCR(Y111∼P) + ZAP70(SH2) <-> TCR(Y111∼P!1).ZAP70(SH2!1) kfZapTcr,krZapTcr 9. ZAP70 binds phosphorylated Y123 in the ζ chain of TCR. ZAP70 has two SH2 domains that bind phosphorylated ITAM residues in the TCR [130] . In the model, the two SH2 domains are treated as a single site. Binding of ZAP70 to phosphorylated pY123 is modeled as follows:
TCR(Y123∼P) + ZAP70(SH2) <-> TCR(Y123∼P!1).ZAP70(SH2!1) kfZapTcr,krZapTcr
10. ZAP70 binds phosphorylated Y199 in the chain of TCR. In addition to binding ITAMs in the TCR ζ chains, ZAP70 is also capable of binding the CD3E ITAM. [127] . Binding of ZAP70 to phosphorylated pY199 is modeled as follows:
TCR(Y199 E∼P) + ZAP70(SH2) <-> TCR(Y199 E∼P!1).ZAP70(SH2!1) kfZapCd3e,krZapCd3e
11. ZAP70 binds phosphorylated Y188 in the chain of TCR. In addition to binding ITAMs in the TCR ζ chains, ZAP70 is also capable of binding the CD3E ITAM. [127] . Binding of ZAP70 to phosphorylated pY188 is modeled as follows:
TCR(Y188 E∼P) + ZAP70(SH2) <-> TCR(Y188 E∼P!1).ZAP70(SH2!1) kfZapCd3e,krZapCd3e
12. PTPN6 binds phosphorylated Y149 in CD3D. PTPN6 (SHP-1) contains two SH2 domains that have been found to bind phosphotyrosines in some cell-surface immunoreceptors [180] . SH2 domain binding disrupts an autoinhibitory intramolecular bond and contributes to PTPN6 activation [181] . Our data indicates that PTPN6 is phosphorylated rapidly, with similar dynamics to sites in proteins known to bind the TCR, such as Y493 in ZAP70 (see Figs. 2, 3, and Supplementary Fig. S6 ). To capture fast recruitment of PTPN6 to the membrane, we assume that it binds phosphotyrosines in the TCR δ and γ ITAMs. We note that interaction of PTPN6 with these sites has not been demonstrated. However, given the large number of phosphosites in the TCR, we take these sites to represent phosphotyrosines that may be bound by PTPN6 without creating competition with ZAP70. PTPN6 may be recruited through other interactions. For example, PTPN6 has recently been found to interact with CRKL [182] . It can also bind the SH2 domain of LCK (see Interaction 24 below); however, this interaction requires phosphorylation of PTPN6 Y566 and therefore cannot account for recruitment of unphosphorylated PTPN6. Recruitment of unphosphorylated PTPN6 is needed for the level of phosphorylated PTPN6 to increase quickly upon stimulation of TCR/CD28 signaling. A role for PTPN6 is supported by a direct test of a model prediction via RNAi knockdown (see Fig. 3 ) as well as our finding that Y192 in LCK is a direct substrate of PTPN6, at least in vitro (Fig. S9 ).
Interactions among receptor-proximal signaling proteins
20. LCK trans-phosphorylates LCK. LCK can be activated by autophosphorylation of Y394 in the kinase domain [193, 194, 195] , which occurs after CD28 binding [196] . Mutations of this site reduce kinase activity [197, 198, 199, 200] .
a. LCK(SH3!1,Y505∼P).CD28(PRS1!1,epitope!2).Lig1(aCD28!2,aCD28!3).
CD28(epitope!3,PRS1!4).LCK(SH3!4,Y394∼0) -> LCK(SH3!1,Y505∼P).CD28(PRS1!1,epitope!2).Lig1(aCD28!2,aCD28!3). CD28(epitope!3,PRS1!4).LCK(SH3!4,Y394∼P) kpLckLck1
b. LCK(SH3!1,Y505∼0).CD28(PRS1!1,epitope!2).Lig1(aCD28!2,aCD28!3).
CD28(epitope!3,PRS1!4).LCK(SH3!4,Y394∼0) ->
LCK(SH3!1,Y505∼0).CD28(PRS1!1,epitope!2).Lig1(aCD28!2,aCD28!3).
CD28(epitope!3,PRS1!4).LCK(SH3!4,Y394∼P) kpLckLck2
The first rule characterizes phosphorylation by autoinhibited LCK (phosphorylated on the inhibitory tyrosine 505), and the second rule characterizes phosphorylation by activated LCK (unphosphorylated on tyrosine 505). The first rule characterizes phosphorylation by autoinhibited LCK (phosphorylated on the inhibitory tyrosine 505), and the second rule characterizes phosphorylation by activated LCK (unphosphorylated on tyrosine 505).
22. LCK phosphorylates ZAP70 Y493. Y493 is located in the activation loop of ZAP70, which can be phosphorylated by SFKs [205] . Phosphorylation of Y493 is necessary for ZAP70 catalytic activity [206, 207] . Mutation of this residue results in markedly reduced tyrosine phosphorylation of ZAP70 and other signaling proteins [207, 208] .
a. TCR(epitope!3,Y111∼P!1).ZAP70(Y493∼0,SH2!1).Lig2(aCD28!2,aCD3!3). The first rule represents binding to LCK that is unphosphorylated at Y192. The second rule represents binding to LCK that is phosphorylated at Y192, which reduces the affinity of the LCK SH2 domain [26] .
Negative regulation by PAG1/CSK 25. CSK binds PAG1. pY317 in PAG binds the SH2 domain of CSK [209] .
26. LCK binds PAG1. pY163 and pY181 in PAG1 are binding sites for SFKs, and these two sites may have redundant functions [31] . Both of these sites are dephosphorylated in our data. For simplicity, we consider only one of them in our model.
27. LCK phosphorylates PAG1 Y317. PAG1 is constitutively phosphorylated in the absence of stimulation. Tyrosine residues in PAG1 are substrates of SFKs [210] .
PAG1(Y317∼0,Y163∼P!1).LCK(SH2!1) -> PAG1(Y317∼P,Y163∼P!1).LCK(SH2!1) kpLckPag
28. CSK phosphorylates LCK. CSK phosphorylates LCK at Y505, which facilitates formation of an inhibitory intramolecular bond. We assume that CSK-mediated phosphorylation of LCK occurs in cis, i.e., when both molecules are bound to the same PAG1 molecule [18] . Dephosphorylation by PTPN6
29. PTPN6 dephosphorylates LCK Y192. Y192 is located within the LCK SH2 domain, and phosphorylation of this site reduces affinity of the SH2 domain for phosphotyrosines [26] . LCK Y192 is rapidly dephosphorylated following TCR/CD28 co-stimulation (see Figs. 2 , 3, and Supplementary Fig. S6 ). Knockdown of PTPN6 results in increased phosphorylation of LCK Y192 (see Fig. 3 ). Thus, we hypothesize that Y192 is a substrate of PTPN6. We note that a proline residue is located at +3 position C-terminal to Y192 (Y(ph)ISPR), which is also found in several reported PTPN6 and PTPN11 substrates [45] . In an in vitro phosphatase assay, we found that PTPN6 is able to directly dephosphorylate Y192 in LCK (Fig. S9 ).
a. LCK(SH3!1,Y192∼P).CD28(PRS1!1,epitope!2).Lig2(aCD28!2,aCD3!3).
TCR ( Rules a and b differ with respect to the TCR site at which PTPN6 is bound.
30. PTPN6 dephosphorylates LCK Y394. Dephosphorylation of LCK Y394 by PTPN6 appears to be a major negative regulatory function of PTPN6 [39] .
a. LCK(SH3!1,Y394∼P).CD28(PRS1!1,epitope!2).Lig2(aCD28!2,aCD3!3).
TCR ( In Rules a and b, LCK and PTPN6 are colocalized through receptor binding. In Rule c, PTPN6 is bound directly to LCK.
31. PTPN6 dephosphorylates PAG1 Y163. PAG1 is observed to be rapidly dephosphorylated following TCR/CD28 co-stimulation. We hypothesize that PAG1 is a substrate of PTPN6. We found that PTPN6 knockdown (KD) resulted in a decrease in phosphorylation of ZAP70 Y493, which is a target of LCK, supporting a a positive role for PTPN6 in early TCR signaling. In the model, the positive effect of PTPN6 KD arises partly because dephosphorylation of PAG1 limits colocalization of LCK and CSK on PAG1 and CSK-mediated phosphorylation of LCK 505 (and LCK autoinhibition). LCK autoinhibition could also be limited if PTPN6 acted directly on LCK pY505. However, it seems that PTPN6-mediated dephosphorylation of pY505 is limited because of intramolecular interaction of pY505 with the LCK SH2 domain [39] . We note that PTPN11 (SHP-2), which is closely related to PTPN6, has been found to act on sites in PAG1 32. PTPN6 dephosphorylates DOK1 pY449. DOK1 pY449 follows a similar time course as other sites of dephosphorylation (see Fig. 2 ). Thus, we hypothesize that it is a substrate of PTPN6, although other phosphatases may be involved (see notes on Interaction 12). DOK1 has been found to be dephosphorylated by PTPN6 [212] , but Y449 has not been specifically identified as a substrate.
a. DOK1 ( 33. PTPN6 dephosphorylates DOK2 pY299. DOK2 pY299 follows a similar time course as other sites of dephosphorylation (see Fig. 2 and Supplementary Fig. S6 ). Thus, we hypothesize that it is a substrate of PTPN6, although other phosphatases may be involved (see notes on Interaction 12).
a. Shortcut recruitment and phosphorylation of WAS 34. NCK1/2 binds WAS. NCK is needed for recruitment of WAS to regions of TCR stimulation [162] . The third SH3 domain of NCK can bind to the central proline-rich region of WAS [171, 172] . This interaction is part of both the long and short pathways for WAS activation. a. TCR(epitope!3,fynbind!1).FYN(unique!1).Lig3(aCD3!2,aCD3!3).
WAS(PRS) + NCK(SH3 3) <-> WAS(PRS!1
TCR(epitope!2,PRS E!4).NCK(SH3 1!4,SH3 3!5).WAS(Y291∼0,PRS!5) ->
